<DOC>
	<DOCNO>NCT01997268</DOCNO>
	<brief_summary>The purpose study investigate effect SC401B ( ethyl ester eicosapentaenoic acid [ EPA ] docosahexaenoic acid [ DHA ] 2 ( ~1260 mg EPA+DHA ) , 4 ( ~2520 mg EPA+DHA ) 6 ( ~3780 mg EPA+DHA ) capsule per day subject hypertriglyceridemia ( triglyceride [ TG ] ≥500 mg/dL ≤ 2,000 mg/dL ) . SC401B capsule also contain certain surfactant may aid absorption EPA DHA . Based result pharmacokinetic study healthy human subject , unlike Lovaza® , EPA DHA SC401B bioavailable fast fed state . The protocol specify primary endpoint difference placebo group percent change TG concentration baseline week 12 group receive 2 , 4 , 6 capsule SC401B per day . The protocol specify secondary endpoint include percent change baseline week 12 total cholesterol ( TC ) , LDL-cholesterol ( LDL-C ) , HDL-cholesterol ( HDL-C ) , non-HDL-cholesterol ( non-HDL-C ) . Additional exploratory variable include VLDL-cholesterol ( VLDL-C ) , LDL-cholesterol particle size , apolipoprotein ( Apo ) A1 , Apo B , Apo C-III , lipoprotein-associated phospholipase A2 ( Lp-PLA2 ) . An additional objective determine tolerability safety SC401B 2 , 4 6 capsule per day 12 week . Adverse event SC401B placebo include burping , fishy taste , upset stomach , loose stool , stool fishy smell self-reported observation evaluate . Additional safety measure include change liver enzymes ( AST/ALT ) occur baseline week 12 group receive 2 , 4 , 6 capsule SC401B placebo .</brief_summary>
	<brief_title>The Efficacy EPA+DHA ( SC401B ) Lowering Triglyceride Levels ( ≥ 500 mg/dL )</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Be male female , age 18 year Have TG level ≥500 mg/dL ≤2,000 mg Have ability understand requirement study willing provide write informed consent ( evidenced signature inform consent document approve Institutional Review Board [ IRB ] ) agree abide study restriction return required assessment . Be normally active good health basis medical history . Willing maintain stable diet alter physical activity level throughout study . Women childbearing potential must willing use accept birth control method throughout study . Women pregnant , plan become pregnant , breastfeed study period History pancreatitis Hemoglobin A1c &gt; 9.5 % ( subject diabetes mellitus require receive stable therapy ) History stroke , myocardial infarction , lifethreatening arrhythmia , coronary vascularization within 6 month screen Thyroidstimulating hormone &gt; 1.5 x upper limit normal ; clinical evidence hypothyroidism thyroid hormonal therapy stable 6 week screen Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 x upper limit normal An unexplained creatine kinase concentration &gt; 3 x upper limit normal creatine kinase elevation due know muscle disease ( e.g. , polymyositis , mitochondrial dysfunction ) Blood donation ≥1 pint within 30 day screen plasma donation within 7 day screen The consumption &gt; 2 alcoholic beverage per day screening ; history illicit drug use within 1 year screen A history symptomatic gallstone disease unless treated cholecystectomy Known nephrotic syndrome &gt; 3 g/day proteinuria Allergy intolerance omega3 fatty acid , ethyl ester , fish ; know lipoprotein lipase impairment deficiency apoCII deficiency familial dysbetalipoproteinemia History cancer ( basal cell carcinoma skin ) past 2 year ; history evidence major clinically significant disease could adversely affect conduct study patient safety . Use acetylcholinesterase inhibitor memantine , prior 2 month screen Use lipase inhibitor Xenical ( orlistat )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Omega-3 Fatty Acids</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>TG ≥500 mg/dL ≤ 2,000 mg/dL</keyword>
</DOC>